DFA: Preliminary Evaluation of a Point-Of-Care Liver Function Test

Sponsor
PATH (Other)
Overall Status
Completed
CT.gov ID
NCT01705041
Collaborator
(none)
700
1
1
6
116.4

Study Details

Study Description

Brief Summary

The proposed preliminary field evaluation will compare a point-of-care (POC) transaminase test with the standard of care test used in an HIV clinic at the Hospital for Tropical Diseases in Ho Chi Minh City, Vietnam.

Condition or Disease Intervention/Treatment Phase
  • Device: Diagnostics for All liver function test (LFT)
N/A

Detailed Description

The DFA transaminase test provides rapid categorical measurement of ALT in a whole blood specimen taken via finger-stick. The test is based on the platform technology of "paper microfluidics" (also known as "patterned paper"), in which hydrophobic barriers are patterned into a sheet of paper in order to create microfluidic, hydrophilic paths within the paper, through which flow can be directed towards specific detection zones. The test is designed for visual color-coded readout in three ALT ranges ("bins") that correspond to the ranges of AST and ALT (<3x the upper limit of normal (ULN), 3-5x ULN, and >5x ULN) currently used for clinical management decisions per US TB and HIV treatment guidelines. The bin cutoffs are common to treatment guidelines used around the globe, including those used by the Vietnam Ministry of Health.

The colorimetric readout is designed to be read by eye using a visual "read guide" allowing the reader to make a semi-quantitative estimate or assign a categorical value into one of three bins. Alternatively, if the device is scanned (e.g. desk-top scanner) or photographed (e.g. cell phone or standard digital camera, see (9)) and read with image-analysis software, it should be possible to generate a quantitative result. Additionally, multiple control zones notify the user of insufficient sample volume, hemolysis, or damaged reagents.

The overall goal of this study is to conduct a preliminary field evaluation of an investigational transaminase test in a population at risk for DILI. The primary objectives are:

  1. Determine device accuracy by measuring the percent agreement of the categorical visual readout DFA transaminase test and the standard of care tests used in the HTD HIV clinic.

  2. Determine inter-operator variability.

  3. Determine device failure rate as defined by invalid test results.

Study Design

Study Type:
Interventional
Actual Enrollment :
700 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Preliminary Field Evaluation of a Point-of-Care Transaminase Test
Study Start Date :
Jun 1, 2012
Actual Primary Completion Date :
Aug 1, 2012
Actual Study Completion Date :
Dec 1, 2012

Arms and Interventions

Arm Intervention/Treatment
Experimental: Diagnostics for All liver function test (LFT)

HIV clinic patients meeting targeted enrollment criteria will give fingerstick blood for use on investigational LFT in comparison to routine transaminase test performed at the clinic lab (gold standard)

Device: Diagnostics for All liver function test (LFT)
HIV clinic patients meeting targeted enrollment criteria will give fingerstick blood for use on investigational LFT in comparison to routine transaminase test performed at the clinic lab (gold standard)
Other Names:
  • Diagnostics for All (DFA) liver function test (LFT)
  • ALT
  • transaminase
  • Outcome Measures

    Primary Outcome Measures

    1. percent agreement with gold standard test [at time of draw]

      Determine device accuracy by measuring the percent agreement of the categorical visual readout DFA transaminase test and the standard of care tests used in the HTD HIV clinic.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Adult (>18 years old) patients receiving HIV treatment through the HTD clinic

    • Must be receiving routine scheduled ALT monitoring on day of enrollment

    • Willing to undergo finger-stick in addition to routine care

    • Must be able to provide informed consent.

    Exclusion Criteria:
    • HIV-negative, or HIV-positive but not on treatment

    • Not receiving transaminase monitoring for routine care

    • Unable or unwilling to provide informed consent

    • Less than 18 years old

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Hospital for Tropical Diseases Ho Chi minh City Vietnam

    Sponsors and Collaborators

    • PATH

    Investigators

    • Principal Investigator: Nira Pollock, MD,PhD, Harvard University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    PATH
    ClinicalTrials.gov Identifier:
    NCT01705041
    Other Study ID Numbers:
    • DFA LFT Study
    First Posted:
    Oct 12, 2012
    Last Update Posted:
    Jan 31, 2013
    Last Verified:
    Jan 1, 2013

    Study Results

    No Results Posted as of Jan 31, 2013